Memory Disorders: Current diagnostics and care 2026

In his comprehensive guide, geriatrician Arvo Haapanen explores the transformative landscape of memory disorders in 2026, marking a pivotal shift from symptomatic management to disease-modifying interventions. The narrative illuminates the intricate biological underpinnings of Alzheimer's disease, specifically the interplay between beta-amyloid plaques and Tau protein tangles, while introducing the newly identified LATE disease. Haapanen emphasizes the critical importance of the Mild Cognitive Impairment (MCI) stage as a window for optimal treatment, supported by groundbreaking AT(N) diagnostics and high-sensitivity blood biomarkers like pTau217.The text bridges the gap between traditional care and cutting-edge science, detailing how anti-amyloid therapies like lecanemab work in tandem with lifestyle interventions such as the FINGER model. By addressing the glymphatic system's role in brain clearance during deep sleep and the impact of chronic inflammation, the guide offers a holistic view of brain health. Beyond clinical pathology, it provides essential guidance on navigating the legal and social complexities of cognitive decline, including driving health assessments and continuing powers of attorney. This synthesis of medical innovation and compassionate care serves as a roadmap for patients and families, replacing the historical hopelessness of dementia with a proactive, evidence-based strategy for extending self-directed, quality life.